A BILL 
Making supplemental appropriations for the fiscal year end-
ing September 30, 2021, providing coronavirus emer-
gency response and relief, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Crush the Virus Act 
4
of 2021’’. 
5
21:09 Feb 26, 2021
H1371
2 
•HR 1371 IH
SEC. 2. FUNDING FOR COVID–19 VACCINE ACTIVITIES AT 
1
THE CENTERS FOR DISEASE CONTROL AND 
2
PREVENTION. 
3
(a) IN GENERAL.—In addition to amounts otherwise 
4
available, there is appropriated to the Secretary of Health 
5
and Human Services (in this Act referred to as the ‘‘Sec-
6
retary’’) for fiscal year 2021, out of any money in the 
7
Treasury not otherwise appropriated, $8,500,000,000, to 
8
remain available until expended, to carry out activities to 
9
plan, prepare for, promote, distribute, administer, mon-
10
itor, and track COVID–19 vaccines, working with States, 
11
territories, and Tribes. 
12
(b) USE OF FUNDS.—The Secretary, acting through 
13
the Director of the Centers for Disease Control and Pre-
14
vention, and in consultation with other agencies, as appli-
15
cable, shall, in conducting activities referred to in sub-
16
section (a)— 
17
(1) enhance, expand, and improve nationwide 
18
COVID–19 vaccine distribution and administration, 
19
including activities related to distribution of ancil-
20
lary medical products and supplies related to vac-
21
cines; 
22
(2) provide for the vaccination of employees and 
23
individuals working or residing in congregate set-
24
tings and other high-risk environments; 
25
21:09 Feb 26, 2021
H1371
3 
•HR 1371 IH
(3) provide information and public outreach, 
1
that is culturally and linguistically appropriate, with 
2
respect to vaccines licensed under section 351 of the 
3
Public Health Service Act (42 U.S.C. 262) or au-
4
thorized under section 564 of the Federal Food, 
5
Drug, and Cosmetic Act (21 U.S.C. 360bbb–3) in 
6
order to strengthen vaccine confidence in the United 
7
States, including its territories and possessions, par-
8
ticularly in minority and underserved communities 
9
with low rates of vaccination; and 
10
(4) provide technical assistance, guidance, and 
11
support to, and award grants or cooperative agree-
12
ments to, State, local, Tribal, and territorial public 
13
health departments for enhancement of COVID–19 
14
vaccine distribution and administration capabilities, 
15
including— 
16
(A) the distribution and administration of 
17
vaccines licensed under section 351 of the Pub-
18
lic Health Service Act (42 U.S.C. 262) or au-
19
thorized under section 564 of the Federal Food, 
20
Drug, and Cosmetic Act (21 U.S.C. 360bbb–3) 
21
and ancillary medical products and supplies re-
22
lated to vaccines; 
23
(B) the establishment and expansion, in-
24
cluding staffing support, of community vaccina-
25
21:09 Feb 26, 2021
H1371
4 
•HR 1371 IH
tion centers, particularly in rural, frontier, and 
1
underserved areas; 
2
(C) the deployment of mobile vaccination 
3
units, particularly in rural, frontier, and under-
4
served areas; 
5
(D) information technology, data, and re-
6
porting enhancements, including improvements 
7
necessary to support sharing of data related to 
8
vaccine distribution and vaccinations and sys-
9
tems that enhance vaccine safety, effectiveness, 
10
and uptake, particularly among underserved 
11
populations; 
12
(E) facilities enhancements; and 
13
(F) communication with the public regard-
14
ing when, where, and how to receive COVID– 
15
19 vaccines. 
16
SEC. 3. FUNDING RESEARCH ON AND DEVELOPMENT OF 
17
COVID–19 VACCINES, THERAPEUTICS, AND 
18
MEDICAL SUPPLIES. 
19
In addition to amounts otherwise available, there is 
20
appropriated to the Public Health and Social Services 
21
Emergency Fund for fiscal year 2021, out of any money 
22
in 
the 
Treasury 
not 
otherwise 
appropriated, 
23
$11,500,000,000, to remain available until expended, for 
24
necessary expenses with respect to research, development, 
25
21:09 Feb 26, 2021
H1371
5 
•HR 1371 IH
manufacturing, production, and the purchase of vaccines, 
1
therapeutics, and ancillary medical products and supplies 
2
to prevent, prepare, or respond to— 
3
(1) SARS–CoV–2 or any viral variant mutating 
4
therefrom with pandemic potential; and 
5
(2) COVID–19 or any disease with potential for 
6
creating a pandemic. 
7
SEC. 4. FUNDING FOR COVID–19 TESTING, CONTACT TRAC-
8
ING, AND MITIGATION ACTIVITIES. 
9
(a) IN GENERAL.—In addition to amounts otherwise 
10
available, there is appropriated to the Secretary for fiscal 
11
year 2021, out of any money in the Treasury not otherwise 
12
appropriated, $50,000,000,000, to remain available until 
13
expended, to carry out activities to detect, diagnose, trace, 
14
and monitor SARS–CoV–2 and COVID–19 infections and 
15
related strategies to mitigate the spread of COVID–19, 
16
working with States, territories, and Tribes. 
17
(b) USE OF FUNDS.—From amounts appropriated by 
18
subsection (a), the Secretary shall— 
19
(1) implement an evidence-based strategy for 
20
testing, contact tracing, surveillance, and mitigation 
21
with respect to SARS–CoV–2 and COVID–19; 
22
(2) provide technical assistance, guidance, and 
23
support, and award grants or cooperative agree-
24
ments to State, local, and territorial public health 
25
21:09 Feb 26, 2021
H1371
6 
•HR 1371 IH
departments for activities to detect, diagnose, trace, 
1
and monitor SARS–CoV–2 and COVID–19 infec-
2
tions and related strategies and activities to mitigate 
3
the spread of COVID–19; 
4
(3) award grants or cooperative agreements to 
5
State, local, Tribal, or territorial public health de-
6
partments or public health laboratories— 
7
(A) to increase their capacity to sequence 
8
genomes of circulating strains of viruses and 
9
other organisms, including SARS–CoV–2; 
10
(B) to identify mutations in viruses and 
11
other organisms, including SARS–CoV–2; 
12
(C) to use genomic sequencing to identify 
13
outbreaks and clusters of diseases or infections, 
14
including COVID–19; and 
15
(D) to develop effective disease response 
16
strategies based on genomic sequencing and 
17
surveillance data; 
18
(4) support the development, manufacturing, 
19
procurement, distribution, and administration of 
20
tests to detect or diagnose SARS–CoV–2 and 
21
COVID–19, including supplies necessary for admin-
22
istering tests, such as personal protective equipment; 
23
(5) establish and expand Federal, State, local, 
24
and territorial testing and contact tracing capabili-
25
21:09 Feb 26, 2021
H1371
7 
•HR 1371 IH
ties, including investments in laboratory capacity, 
1
community-based testing sites, and mobile testing 
2
units, particularly in rural, frontier, and medically 
3
underserved areas; 
4
(6) enhance information technology, data mod-
5
ernization, and reporting, including improvements 
6
necessary to support sharing of data related to pub-
7
lic health capabilities; 
8
(7) award grants to, or enter into cooperative 
9
agreements or contracts with, State, local, and terri-
10
torial public health departments to establish, ex-
11
pand, and sustain a public health workforce; and 
12
(8) to cover administrative and program sup-
13
port costs necessary to conduct activities related to 
14
subparagraph (a). 
15
SEC. 5. FEDERAL EMERGENCY MANAGEMENT AGENCY AP-
16
PROPRIATION. 
17
In addition to amounts otherwise available, there is 
18
appropriated to the Federal Emergency Management 
19
Agency for fiscal year 2021, out of any money in the 
20
Treasury not otherwise appropriated, $30,000,000,000, to 
21
remain available until September 30, 2025, for major dis-
22
asters declared pursuant to the Robert T. Stafford Dis-
23
aster Relief and Emergency Assistance Act (42 U.S.C. 
24
5121 et seq.). 
25
19:44 Mar 23, 2021
H1371
8 
•HR 1371 IH
SEC. 6. COVID–19 EMERGENCY MEDICAL SUPPLIES EN-
1
HANCEMENT. 
2
(a) SUPPORTING ENHANCED USE OF THE DEFENSE 
3
PRODUCTION ACT OF 1950.—In addition to funds other-
4
wise available, there is appropriated, for fiscal year 2021, 
5
out of any money in the Treasury not otherwise appro-
6
priated, $5,000,000,000, to remain available until Sep-
7
tember 30, 2025, to carry out titles I, III, and VII of the 
8
Defense Production Act of 1950 (50 U.S.C. 4501 et seq.) 
9
in accordance with subsection (b). 
10
(b) MEDICAL SUPPLIES AND EQUIPMENT.—Amounts 
11
appropriated in subsection (a) shall be used for the pur-
12
chase, production (including the construction, repair, and 
13
retrofitting of government-owned or private facilities as 
14
necessary), or distribution of medical supplies and equip-
15
ment (including durable medical equipment) related to 
16
combating the COVID–19 pandemic, including— 
17
(1) in vitro diagnostic products (as defined in 
18
section 809.3(a) of title 21, Code of Federal Regula-
19
tions) for the detection of SARS–CoV–2 or the diag-
20
nosis of the virus that causes COVID–19, and the 
21
reagents and other materials necessary for pro-
22
ducing, conducting, or administering such products, 
23
and the machinery, equipment, laboratory capacity, 
24
or other technology necessary to produce such prod-
25
ucts; 
26
21:09 Feb 26, 2021
H1371
9 
•HR 1371 IH
(2) face masks and personal protective equip-
1
ment, including face shields, nitrile gloves, N–95 fil-
2
tering facepiece respirators, and any other masks or 
3
equipment (including durable medical equipment) 
4
determined by the Secretary of Health and Human 
5
Services to be needed to respond to the COVID–19 
6
pandemic, and the materials, machinery, additional 
7
manufacturing lines or facilities, or other technology 
8
necessary to produce such equipment; and 
9
(3) drugs and devices (as those terms are de-
10
fined in the Federal Food, Drug, and Cosmetic Act 
11
(21 U.S.C. 301 et seq.)) and biological products (as 
12
that term is defined by section 351 of the Public 
13
Health Service Act (42 U.S.C. 262)) that are ap-
14
proved, cleared, licensed, or authorized under either 
15
of such Acts for use in treating or preventing 
16
COVID–19 and symptoms related to COVID–19, 
17
and any materials, manufacturing machinery, addi-
18
tional manufacturing or fill-finish lines or facilities, 
19
technology, or equipment (including durable medical 
20
equipment) necessary to produce or use such drugs, 
21
biological products, or devices (including syringes, 
22
vials, or other supplies or equipment related to deliv-
23
ery, distribution, or administration). 
24
21:09 Feb 26, 2021
H1371
10 
•HR 1371 IH
(c) DELEGATION
AUTHORITY.—For purposes of 
1
using amounts appropriated in subsection (a), the Presi-
2
dent shall only delegate authority to, with respect to any 
3
uses described under subsection (b)— 
4
(1) the Secretary of Health and Human Serv-
5
ices; and 
6
(2) the head of any other agency responsible for 
7
responding to the COVID–19 pandemic if the Presi-
8
dent determines that such delegation is important to 
9
an effective response to such pandemic. 
10
(d) APPLICATION OF LIMITATIONS UNDER THE DE-
11
FENSE PRODUCTION ACT OF 1950.—The requirements 
12
described in section 304(e) of the Defense Production Act 
13
of 1950 (50 U.S.C. 4534(e)) shall not apply to the funds 
14
appropriated in subsection (a) until September 30, 2025. 
15
SEC. 7. PERSONAL PROTECTIVE EQUIPMENT. 
16
In addition to amounts otherwise available, there is 
17
appropriated to the Secretary for fiscal year 2021, out of 
18
any money in the Treasury not otherwise appropriated, 
19
$5,000,000,000 to remain available until expended, for 
20
necessary expenses with respect to the manufacturing, ac-
21
quisition, and distribution of personal protective equip-
22
ment for preventing the spread of COVID–19. 
23
21:09 Feb 26, 2021
H1371
11 
•HR 1371 IH
SEC. 8. STRATEGIC NATIONAL STOCKPILE. 
1
In addition to amounts otherwise available, there is 
2
appropriated to the Secretary for fiscal year 2021, out of 
3
any money in the Treasury not otherwise appropriated, 
4
$15,000,000,000, to remain available until expended, for 
5
necessary expenses with respect to the procurement and 
6
stockpile pursuant to section 319F–2 of the Public Health 
7
Service Act (42 U.S.C. 247d–6b) of vaccines, therapeutics, 
8
and ancillary medical products and supplies to prevent, 
9
prepare, or respond to SARS–CoV–2 or any viral variant 
10
mutating therefrom with pandemic potential, and 
11
COVID–19. 
12
SEC. 9. PROVIDER RELIEF FUND. 
13
(a) In addition to amounts otherwise available, there 
14
is appropriated for the Public Health and Social Services 
15
Emergency Fund for fiscal year 2021, out of any money 
16
in 
the 
Treasury 
not 
otherwise 
appropriated, 
17
$35,000,000,000, to remain available until expended, to 
18
prevent, prepare for, and respond to COVID–19, domesti-
19
cally or internationally, for necessary expenses to reim-
20
burse, through grants or other mechanisms, eligible health 
21
care providers for health care related expenses or lost reve-
22
nues that are attributable to coronavirus. 
23
(b) Of the eligible health care providers that are re-
24
cipients of payments under this section, $7,000,000,000 
25
of such amount shall be for suppliers and providers located 
26
21:09 Feb 26, 2021
H1371
12 
•HR 1371 IH
in a rural area (as defined in section 1886(d)(2)(D) of 
1
the Social Security Act (42 U.S.C. 1395ww(d)(2)(D))). 
2
(c) These funds may not be used to reimburse ex-
3
penses or losses that have been reimbursed from other 
4
sources or that other sources are obligated to reimburse. 
5
(d) Recipients of payments under this section shall 
6
submit reports and maintain documentation as the Sec-
7
retary determines are needed to ensure compliance with 
8
conditions that are imposed by this section for such pay-
9
ments, and such reports and documentation shall be in 
10
such form, with such content, and in such time as the Sec-
11
retary may prescribe for such purpose. 
12
(e) The term ‘‘eligible health care providers’’ means 
13
public entities, Medicare or Medicaid enrolled suppliers 
14
and providers, and such for-profit entities and not-for- 
15
profit entities not otherwise described in this subsection 
16
as the Secretary may specify, within the United States (in-
17
cluding territories), that provide diagnoses, testing, or 
18
care for individuals with possible or actual cases of 
19
COVID–19. 
20
(f) The Secretary of Health and Human Services 
21
shall, on a rolling basis, review applications and make pay-
22
ments under this section in this Act. 
23
(g) Funds appropriated under this section in this Act 
24
shall be available for building or construction of temporary 
25
22:51 Feb 26, 2021
H1371
13 
•HR 1371 IH
structures, leasing of properties, medical supplies and 
1
equipment including personal protective equipment and 
2
testing supplies, increased workforce and trainings, emer-
3
gency operation centers, retrofitting facilities, and surge 
4
capacity. 
5
(h) In this section, the term ‘‘payment’’ means a pre- 
6
payment, prospective payment, or retrospective payment, 
7
as determined appropriate by the Secretary. 
8
(i) Payments under this section shall be made in con-
9
sideration of the most efficient payment systems prac-
10
ticable to provide emergency payment. 
11
(j) To be eligible for a payment under this section, 
12
an eligible health care provider shall submit to the Sec-
13
retary of Health and Human Services an application that 
14
includes a statement justifying the need of the provider 
15
for the payment and the eligible health care provider shall 
16
have a valid tax identification number. 
17
(k) Not later than 3 years after final payments are 
18
made under this section, the Office of Inspector General 
19
of the Department of Health and Human Services shall 
20
transmit a final report on audit findings with respect to 
21
this program to the Committees on Appropriations of the 
22
House of Representatives and the Senate. 
23
21:09 Feb 26, 2021
H1371
14 
•HR 1371 IH
(l) Nothing in this section limits the authority of the 
1
Inspector General or the Comptroller General to conduct 
2
audits of interim payments at an earlier date. 
3
(m) Not later than 60 days after the date of enact-
4
ment of this Act, the Secretary of Health and Human 
5
Services shall provide a report to the Committees on Ap-
6
propriations of the House of Representatives and the Sen-
7
ate on obligation of funds, including obligations to such 
8
eligible health care providers summarized by State of the 
9
payment receipt. 
10
(n) Such reports shall be updated and submitted to 
11
such Committees every 60 days until funds are expended. 
12
SEC. 10. FUNDING FOR BLOCK GRANTS FOR COMMUNITY 
13
MENTAL HEALTH SERVICES. 
14
In addition to amounts otherwise available, there is 
15
appropriated to the Secretary for fiscal year 2021, out of 
16
any money in the Treasury not otherwise appropriated, 
17
$1,750,000,000, to remain available until expended, for 
18
carrying out subpart I of part B of title XIX of the Public 
19
Health Service Act (42 U.S.C. 300x et seq.), subpart III 
20
of part B of title XIX of such Act (42 U.S.C. 300x–51 
21
et seq.), and section 505(c) of such Act (42 U.S.C. 290aa– 
22
4(c)) with respect to mental health. Notwithstanding sec-
23
tion 1952 of the Public Health Service Act (42 U.S.C. 
24
300x–62), any amount awarded to a State out of amounts 
25
21:09 Feb 26, 2021
H1371
15 
•HR 1371 IH
appropriated by this section shall be expended by the State 
1
by September 30, 2025. 
2
SEC. 11. FUNDING FOR BLOCK GRANTS FOR PREVENTION 
3
AND TREATMENT OF SUBSTANCE ABUSE. 
4
In addition to amounts otherwise available, there is 
5
appropriated to the Secretary for fiscal year 2021, out of 
6
any money in the Treasury not otherwise appropriated, 
7
$1,750,000,000, to remain available until expended, for 
8
carrying out subpart II of part B of title XIX of the Public 
9
Health Service Act (42 U.S.C. 300x–21 et seq.), subpart 
10
III of part B of title XIX of such Act (42 U.S.C. 300x– 
11
51 et seq.), section 505(d) of such Act (42 U.S.C. 290aa– 
12
4(d)) with respect to substance abuse, and section 515(d) 
13
of such Act (42 U.S.C. 290bb–21(d)). Notwithstanding 
14
section 1952 of the Public Health Service Act (42 U.S.C. 
15
300x–62), any amount awarded to a State out of amounts 
16
appropriated by this section shall be expended by the State 
17
by September 30, 2025. 
18
SEC. 12. MISCELLANEOUS PROVISIONS. 
19
(a) APPLICABLE REQUIREMENTS.—Amounts appro-
20
priated by this Act are subject to the requirements con-
21
tained in Public Law 116–94 for funds for programs au-
22
thorized under sections 330 through 340 of the Public 
23
Health Service Act (42 U.S.C. 254b et seq.). 
24
21:09 Feb 26, 2021
H1371
16 
•HR 1371 IH
(b) EMERGENCY DESIGNATION.—Amounts appro-
1
priated by this Act are designated by the Congress as 
2
being for an emergency requirement pursuant to section 
3
251(b)(2)(A)(i) of the Balanced Budget and Emergency 
4
Deficit Control Act of 1985. 
5
Æ 
21:09 Feb 26, 2021
H1371
